The latest price target for Sensei Biotherapeutics (NASDAQ:SNSE) was reported by HC Wainwright & Co. on August 7, 2024. The analyst firm set a price target for $4.00 expecting SNSE to rise to within 12 months (a possible 716.33% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Sensei Biotherapeutics (NASDAQ:SNSE) was provided by HC Wainwright & Co., and Sensei Biotherapeutics reiterated their buy rating.

The last upgrade for Sensei Biotherapeutics Inc happened on October 3, 2022 when Oppenheimer raised their price target to $5. Oppenheimer previously had a perform for Sensei Biotherapeutics Inc.

There is no last downgrade for Sensei Biotherapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sensei Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sensei Biotherapeutics was filed on August 7, 2024 so you should expect the next rating to be made available sometime around August 7, 2025.

While ratings are subjective and will change, the latest Sensei Biotherapeutics (SNSE) rating was a reiterated with a price target of $4.00 to $4.00. The current price Sensei Biotherapeutics (SNSE) is trading at is $0.49, which is out of the analyst’s predicted range.